Gaining trust through transparency: the EMERGENT-2 trial - Authors' reply.

Autor: Kaul I; Karuna Therapeutics, a Bristol Myers Squibb company, Princeton, NJ 08540, USA., Breier A; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA., Miller AC; Karuna Therapeutics, a Bristol Myers Squibb company, Princeton, NJ 08540, USA., Paul SM; Karuna Therapeutics, a Bristol Myers Squibb company, Princeton, NJ 08540, USA. Electronic address: smpaulmd@gmail.com., Brannan SK; Karuna Therapeutics, a Bristol Myers Squibb company, Princeton, NJ 08540, USA.
Jazyk: angličtina
Zdroj: Lancet (London, England) [Lancet] 2024 Aug 10; Vol. 404 (10452), pp. 524.
DOI: 10.1016/S0140-6736(24)01269-8
Databáze: MEDLINE